GlassScriptPhysician profile
Eugene J Choi
NPI 1457593675
$3,212.19
in general payments reported to CMS, 2019-2025
38 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $111 · 2021: $491 · 2022: $265 · 2023: $1,458 · 2024: $63.56 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Education: $44.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.92 |
| Education | $44.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.41 | 2019-2023 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $313.43 | 2019-2025 | Eliquis, Opdivo, Camzyos |
| Astellas Pharma US INC | $211.60 | 2019-2025 | Padcev, Xtandi, Xospata |
| Pfizer INC. | $206.54 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $184.62 | 2019 | |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Celgene Corporation | $147.47 | 2019-2023 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $139.37 | 2019-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $125.08 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $124.84 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genzyme Corporation | $108.10 | 2021-2023 | |
| Genentech USA, INC. | $106.22 | 2019-2025 | Venclexta, Polivy |
| Lilly USA, LLC | $99.34 | 2019-2021 | |
| Daiichi Sankyo INC. | $89.99 | 2022-2023 | Enhertu |
| Incyte Corporation | $86.39 | 2022-2023 | Monjuvi, Pemazyre |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $67.01 | 2021-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $63.52 | 2019-2023 | Alunbrig |
| Blueprint Medicines Corporation | $56.28 | 2020-2023 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $52.27 | 2021-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $50.56 | 2021-2023 | |
| Glaxosmithkline, LLC. | $48.45 | 2022-2023 | Ojjaara |
| Abbvie INC. | $46.87 | 2023 | Venclexta |
| Array Biopharma INC | $46.56 | 2021-2023 | Mektovi, Lorbrena, Braftovi |
| Myriad Genetic Laboratories, INC. | $41.48 | 2022-2023 | Myrisk |
| Mirati Therapeutics, INC. | $37.45 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $36.16 | 2019-2021 | |
| Novocure INC. | $34.23 | 2025 | Optune Gio |
| Tempus Ai, INC | $34.06 | 2025 | Xt Cdx |
| Amgen INC. | $23.53 | 2020 | |
| Kyowa Kirin, INC. | $22.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.12 | 2019 | |
| Morphosys, US INC. | $18.11 | 2023 | Monjuvi |
| Emd Serono, INC. | $16.86 | 2021 | |
| Deciphera Pharmaceuticals INC. | $16.55 | 2023 | Qinlock |
| Stemline Therapeutics INC. | $16.29 | 2021 | |
| Caris Mpi, INC. | $15.46 | 2025 | Mi Cancer Seek |
| Shield Therapeutics INC | $15.21 | 2025 | |
| Sumitomo Pharma America, INC. | $13.99 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.